Država: Kanada
Jezik: angleščina
Source: Health Canada
TELMISARTAN
ALEMBIC PHARMACEUTICALS LIMITED
C09CA07
TELMISARTAN
80MG
TABLET
TELMISARTAN 80MG
ORAL
30/100
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0138223002; AHFS:
APPROVED
2018-07-23
______________________________________________________________________________ _Alembic-Telmisartan Product Monograph_ _ Page 1 of 39_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ALEMBIC-TELMISARTAN Telmisartan Tablets Tablets, 40 mg and 80 mg, Oral USP Angiotensin II AT1 Receptor Blocker Manufactured by: Date of Initial Authorization: Alembic Pharmaceuticals Limited July 23, 2018 Alembic Road, Vadodara 390003, Gujarat, India Canadian Importer and Distributor: Date of Revision: Alembic Pharmaceuticals Canada Ltd. June 29, 2023 2680, Matheson Blvd. East, Unit 102 Mississauga, Ontario L4W 0A5, Canada Submission Control Number: 271582 ______________________________________________________________________________ _Alembic-Telmisartan Product Monograph_ _ Page 2 of 39_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 07/2023 7 WARNINGS AND PRECAUTIONS 07/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS…………....……………………………………………………………………………………………….2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ................................................................................................................... 4 1.1 Pediatrics ..................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................................................. 5 4 DOSAGE AND ADMINISTRATION ....................................................................................... 5 4.1 Dosing Considerations .................. Preberite celoten dokument